Exact Sciences Corporation (NASDAQ:EXAS) went down by -6.26% from its latest closing price compared to the recent 1-year high of $133.99. The company’s stock price has collected -18.77% of loss in the last five trading sessions. Barron’s reported on 05/04/21 that Shares of Cancer Researchers Exact Sciences and Invitae Are Sliding. Here’s Why.
Is It Worth Investing in Exact Sciences Corporation (NASDAQ :EXAS) Right Now?
Plus, the 36-month beta value for EXAS is at 1.23. Opinions of the stock are interesting as 14 analysts out of 19 who provided ratings for Exact Sciences Corporation declared the stock was a “buy,” while 3 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $99.44, which is $51.24 above the current price. EXAS currently public float of 174.39M and currently shorts hold a 7.79% ratio of that float. Today, the average trading volume of EXAS was 1.96M shares.
EXAS’s Market Performance
EXAS stocks went down by -18.77% for the week, with a monthly drop of -27.56% and a quarterly performance of -41.60%, while its annual performance rate touched -49.85%. The volatility ratio for the week stands at 8.94% while the volatility levels for the past 30 days are set at 7.30% for Exact Sciences Corporation. The simple moving average for the period of the last 20 days is -20.54% for EXAS stocks with a simple moving average of -42.13% for the last 200 days.
Analysts’ Opinion of EXAS
Many brokerage firms have already submitted their reports for EXAS stocks, with Raymond James repeating the rating for EXAS by listing it as a “Outperform.” The predicted price for EXAS in the upcoming period, according to Raymond James is $130 based on the research report published on November 03rd of the previous year 2021.
Stifel, on the other hand, stated in their research note that they expect to see EXAS reach a price target of $145, previously predicting the price at $165. The rating they have provided for EXAS stocks is “Buy” according to the report published on July 29th, 2021.
Oppenheimer gave a rating of “Outperform” to EXAS, setting the target price at $155 in the report published on July 29th of the previous year.
EXAS Trading at -26.28% from the 50-Day Moving Average
After a stumble in the market that brought EXAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.03% of loss for the given period.
Volatility was left at 7.30%, however, over the last 30 days, the volatility rate increased by 8.94%, as shares sank -28.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.99% lower at present.
During the last 5 trading sessions, EXAS fell by -18.77%, which changed the moving average for the period of 200-days by -56.95% in comparison to the 20-day moving average, which settled at $59.70. In addition, Exact Sciences Corporation saw -38.07% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at EXAS starting from Elliott Jeffrey Thomas, who sale 4,050 shares at the price of $76.69 back on Mar 01. After this action, Elliott Jeffrey Thomas now owns 19,128 shares of Exact Sciences Corporation, valued at $310,594 using the latest closing price.
COWARD D SCOTT, the Chief Legal Officer of Exact Sciences Corporation, sale 3,912 shares at $76.69 during a trade that took place back on Mar 01, which means that COWARD D SCOTT is holding 16,234 shares at $300,011 based on the most recent closing price.
Stock Fundamentals for EXAS
Current profitability levels for the company are sitting at:
- -41.27 for the present operating margin
- +68.66 for the gross margin
The net margin for Exact Sciences Corporation stands at -33.71. Equity return is now at value -21.80, with -11.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.76.